Comment by
subaru1 on Apr 30, 2024 2:44pm
But still not on the big radar, not much volume compare to the BIG one, but things are getting better for sure.
Comment by
Lvlchange on Apr 30, 2024 2:58pm
The others are up 50%. Nobody freaking knows who we are LOL!
Comment by
okgonow on Apr 30, 2024 3:00pm
yes all other pot stocks are getting a very nice bump today again shows you that our PR machine is a mouse MPL is going to be one of the companys that benifits the most by DEA decisssion but we get screwed as shareholders because no one knows about us Pidduck i am sure BNN would be glad to do a interview where you could blow our horn as we are a POT PHARMA COMPANY
Comment by
Starkicker on Apr 30, 2024 3:03pm
With this news and what should be a strong Q1 report, might be a good time to take the hood off this thing and bring to light all the secrecy and get this SP headed north.
Comment by
okgonow on Apr 30, 2024 3:09pm
why anyone would sell at below $.15 at this point is beond me actualy why anyone would sell below $.25 is an idiot and when Q 1 comes out they will kick themselves for selling at that price
Comment by
okgonow on Apr 30, 2024 3:10pm
also we should be trading Millions of shares with this news
Comment by
okgonow on Apr 30, 2024 3:12pm
In Q4 2023, Medipharm completed the development and initial deliveries of THC (tetrahydrocannabinol) isolate, commonly known as dronabinol, for the European Union market. Subsequent to year-end, Medipharm has made deliveries of this product to multiple customers, and it anticipates it having a materially positive impact to sales and gross profit.
Comment by
okgonow on Apr 30, 2024 3:19pm
2023 full-year revenue increased approximately 50 per cent 2023 full-year adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) improved 50 per cent Q4 2023 adjusted EBITDA improved 55 per cent Strong balance sheet, relative to many peer companies, with approximately $18-million of cash and less than $3-million of debt as of Dec. 31, 2023.